# Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Study · id `cardio:ct-nct01879319` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01879319](<https://clinicaltrials.gov/study/NCT01879319>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01879319

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.

## Technical summary

Registry record NCT01879319. Randomized; no masking; primary purpose treatment. Start 2013-07-11 (actual); primary completion 2013-11-15 (actual). Results posted on 2015-12-23.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 164 participants (enrolled count; ClinicalTrials.gov record NCT01879319, source copy `cardio:ctgov-nct01879319-2022-11-30`, retrieved 2026-10-31)
- Started: 2013-07-11 (actual) (ClinicalTrials.gov record NCT01879319, source copy `cardio:ctgov-nct01879319-2022-11-30`, retrieved 2026-10-31)
- Primary completion: 2013-11-15 (actual) (ClinicalTrials.gov record NCT01879319, source copy `cardio:ctgov-nct01879319-2022-11-30`, retrieved 2026-10-31)
- Completion: Not reported
- Results first posted: 2015-12-23 (ClinicalTrials.gov record NCT01879319, source copy `cardio:ctgov-nct01879319-2022-11-30`, retrieved 2026-10-31)
- Countries: United States; Canada (ClinicalTrials.gov record NCT01879319, source copy `cardio:ctgov-nct01879319-2022-11-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01879319-2022-11-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
- Condition: Primary Hypercholesterolemia
- Condition: Mixed Dyslipidemia
- Intervention (Biological): Evolocumab AMD
- Intervention (Biological): Evolocumab AI/pen
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 59beeaae2e6176ef4a666d2d4da9b1c45358d90d98cc7f94b24e6f86e6a07745
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
